What's in Shenzhen Salubris Pharmaceuticals Co., Ltd.'s pipeline?

Shenzhen Salubris Pharmaceuticals Co., Ltd. has 13 drugs in our index: 2 marketed, 0 filed, 5 in Phase 3, 0 in Phase 2, 6 in Phase 1.

Which companies overlap with Shenzhen Salubris Pharmaceuticals Co., Ltd.'s portfolio?

Top competitors by shared drug class: Sanofi, University of Chicago, GlaxoSmithKline, Merck Sharp & Dohme LLC, Takeda.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shenzhen-salubris-pharmaceuticals-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shenzhen Salubris Pharmaceuticals Co., Ltd. pipeline: 2 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 5 Phase 3 0 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Enarodustat 2mg	Enarodustat 2mg	marketed
FORSTEO	FORSTEO	marketed	Parathyroid hormone analog	PTH1 receptor	Endocrinology / Bone Metabolism
SAL067	SAL067	phase 3
SAL-0951	SAL-0951	phase 3
SAL056 (56.5μg)	SAL056 (56.5μg)	phase 3	Inhaled corticosteroid	Glucocorticoid receptor	Respiratory / Pulmonology
Allisartan Isoproxil/Sustained-Release Indapamide	Allisartan Isoproxil/Sustained-Release Indapamide	phase 3	Angiotensin II receptor blocker / Thiazide-like diuretic combination	Angiotensin II type 1 receptor (AT1R) / Sodium-chloride cotransporter (NCC)	Cardiovascular
SAL-0951 tablets	SAL-0951 tablets	phase 3	SGLT2 inhibitor	SGLT2	Diabetes

Therapeutic area mix

Cardiovascular · 1
Diabetes · 1
Endocrinology / Bone Metabolism · 1
Respiratory / Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sanofi · 2 shared drug classes
University of Chicago · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Takeda · 2 shared drug classes
Teva Branded Pharmaceutical Products R&D, Inc. · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shenzhen Salubris Pharmaceuticals Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shenzhen Salubris Pharmaceuticals Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shenzhen-salubris-pharmaceuticals-co-ltd. Accessed 2026-05-16.